SCHEMBL253522

SCHEMBL253522

COc1ccccc1-c1cc(=O)c2ccccc2o1

nearest known ligand 0.78

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 9/20 0.78
CYP3A4 P08684 9/20 0.78
ALDH1A1 P00352 7/20 0.78
MAPT P10636 6/20 0.78
SMN1; SMN2 Q16637 5/20 0.78
CYP2C19 P33261 5/20 0.78
MEN1 O00255 5/20 0.78
KMT2A Q03164 5/20 0.78
RAB9A P51151 4/20 0.78
CYP2C9 P11712 4/20 0.78
TSHR P16473 3/20 0.78
MAPK1 P28482 3/20 0.78
NPC1 O15118 3/20 0.78
CYP2D6 P10635 3/20 0.78
TP53 P04637 3/20 0.78
CYP1A2 P05177 2/20 0.78
ALOX15 P16050 2/20 0.78
GMNN O75496 1/20 0.78
RAF1 P04049 1/20 0.78
PKM P14618 1/20 0.78

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4649187 0.89 HPGD (0.74) HPGDCYP3A4ALDH1A1MAPTSMN1; SMN2
SCHEMBL29504929 0.88 HPGD (1.00) HPGDCYP3A4ALDH1A1MAPTSMN1; SMN2
SCHEMBL157826 0.88 HPGD (1.00) HPGDCYP3A4ALDH1A1MAPTSMN1; SMN2
SCHEMBL11289655 0.88 HPGD (0.73) HPGDCYP3A4ALDH1A1MAPTSMN1; SMN2
Water SCHEMBL8404969 0.86 HPGD (0.97) HPGDCYP3A4ALDH1A1MAPTSMN1; SMN2
SCHEMBL30089725 0.86 AR (0.72) HPGDCYP3A4ALDH1A1MAPTSMN1; SMN2
SCHEMBL30660103 0.86 AR (1.00) HPGDCYP3A4ALDH1A1MAPTSMN1; SMN2
SCHEMBL4649397 0.86 AR (0.72) HPGDCYP3A4ALDH1A1MAPTSMN1; SMN2
7,2'-Dimethoxyflavone SCHEMBL4285153 0.86 AR (0.81) HPGDCYP3A4ALDH1A1MAPTSMN1; SMN2
SCHEMBL4443406 0.86 AR (1.00) HPGDCYP3A4ALDH1A1MAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1280 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250282871-A1 PHARMACEUTICAL COMBINATION AND USE THEREOF TIANJIN LIPOGEN TECH CO LTD (CN) 2025-09-11 US claimed
US-12239655-B2 Combined modalities for nucleosides and/or NADPH oxidase (NOX) inhibitors as myeloid-specific antiviral agents EMORY UNIVERSITY (US) 2025-03-04 US claimed
EP-4384027-A1 COMPOSITION COMPRISING A NUTRIENT AND A TASTE MODULATOR Firmenich SA (CH) 2024-06-19 EP claimed
WO-2024114248-A1 CITRUS FRUIT EXTRACT, AND PREPARATION METHOD THEREFOR AND USE THEREOF 三峡大学 2024-06-06 WO claimed
EP-4342492-A1 PHARMACEUTICAL COMBINATION AND USE THEREOF Tianjin Lipogen Technology Co., Ltd (CN) 2024-03-27 EP claimed
EP-4329499-A1 FLAVOR-MODIFYING COMPOSITIONS CONTAINING LACTASE Firmenich SA (CH) 2024-03-06 EP claimed
WO-2023108169-A2 METHODS AND COMPOSITIONS FOR THE BIOSYNTHESIS AND USE OF DEMETHYLATED POLYMETHOXY FLAVONES RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2023-06-15 WO claimed
WO-2023072604-A1 COMPOSITION COMPRISING A NUTRIENT AND A TASTE MODULATOR FIRMENICH SA (CH) 2023-05-04 WO claimed
CN-115948362-A Oxygen methyltransferase participating in biosynthesis of polymethoxyflavone in citrus peel, coding gene, amplification primer pair and application 浙江大学 2023-04-11 CN claimed
CN-115813991-A Application of citrus fruit extract in preparation of medicine for treating breast cancer endocrine 三峡大学 2023-03-21 CN claimed
US-20020016358-A1 Cosmetic composition NOF CORPORATION 2002-02-07 US claimed
US-20020006953-A1 MODIFICATION OF CHOLESTEROL CONCENTRATIONS WITH CITUS PHYTOCHEMICALS TROPICANA PRODUCTS, INC. 2002-01-17 US claimed
EP-1147764-A2 Cosmetic composition NOF CORPORATION (JP) 2001-10-24 EP claimed
CN-1318366-A Cosmetics composition NIPPON OILS & FATS CO LTD (JP) 2001-10-24 CN claimed
WO-2001070029-A1 COMPOSITIONS AND METHODS OF TREATING, REDUCING, AND PREVENTING CARDIOVASCULAR DISEASES AND DISORDERS WITH POLYMETHOXYFLAVONES KGK SYNERGIE (CA) 2001-09-27 WO claimed
WO-2001032160-A2 MODIFICATION OF CHOLESTEROL CONCENTRATIONS WITH CITRUS PHYTOCHEMICALS TROPICANA PRODUCTS, INC. (US) 2001-05-10 WO claimed
WO-2001021137-A1 EXTRACTS OF ORANGE PEEL FOR PREVENTION AND TREATMENT OF CANCER RUTGERS, THE STATE UNIVERSITY (US) 2001-03-29 WO claimed
WO-2001003681-A2 USE OF FLAVONES, COUMARINS AND RELATED COMPOUNDS TO TREAT INFECTIONS PRENDERGAST PATRICK T (IE) 2001-01-18 WO claimed
WO-1996031206-A2 FLAVONES AND COUMARINS AS AGENTS FOR THE TREATMENT OF ATHEROSCLEROSIS WARNER-LAMBERT COMPANY (US) 1996-10-10 WO claimed
US-5399584-A Preventing gastrointestinal damage caused by nonsteroidal antiinflammatory drugs THE PROCTER & GAMBLE COMPANY (US) 1995-03-21 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020016358-A1 Cosmetic composition PLIN5, TEAD3, CUTA HPGD 1414/4885CYP3A4 3800/4885ALDH1A1 3843/4885
US-12239655-B2 Combined modalities for nucleosides and/or NADPH oxidase (NOX) inhibitors as myeloid-specific antiviral agents NOX1, NOX3, NOX4 HPGD 256/4885CYP3A4 1105/4885ALDH1A1 1165/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.